Divi's Laboratories Limited (DIVISLAB) share price and analysis
DIVISLAB last traded at ₹11,150.00 (+0.63%) on the NSE. Market cap ₹2,95,997 Cr (Large cap), Pharma & Healthcare sector.
Overall rating: 8.0/10 (Excellent)
- Valuation: 2.8/10
- Profitability: 10.0/10
- Growth: 10.0/10
- Financial health: 7.3/10
- Price trend: 9.8/10
Long-term view: Strong long-term candidate. Business quality and valuation clearly outweigh the weaknesses. Trade bias (next few weeks): Strong long. Trend and momentum are clearly pointing up.
Strengths of DIVISLAB
- Return on equity (20.1%): Earns ₹20 profit for every ₹100 of shareholder capital, which is excellent capital efficiency.
- Debt / equity (0.00): Virtually debt-free, with a strong balance sheet.
- Long-term trend (+47.5% vs 200-DMA): Trading well above its 200-day average, a clear long-term uptrend.
- Net profit margin (27.6%): Keeps ₹28 as profit from every ₹100 of revenue, a high-margin business.
- Revenue growth (YoY) (+35.4%): Sales are growing fast.
- Profit growth (YoY) (+63.6%): Profits are growing rapidly.
- 50-DMA vs 200-DMA (+27.8% gap): 50-day average is above the 200-day (golden-cross setup), so medium-term momentum is up.
- 6-month performance vs Nifty 50 (+64.9% vs +7.4%): Strongly outperforming the Nifty 50 over 6 months.
- Momentum (RSI 14) (RSI 69): Strong bullish momentum without being overbought.
- Current ratio (4.59): Plenty of short-term assets to cover short-term bills.
- 52-week range (6% below high): Trading near its 52-week high, so buyers are in control.
- Volatility (1Y) (26% annualised): Below-average volatility.
Weaknesses of DIVISLAB
- Valuation (P/E) (P/E 88.0 vs sector 41.1): Expensive at 2.1× the sector median P/E. High expectations are already priced in.
- Free cash flow (Negative): Burning cash, because free cash flow is negative. Growth is being funded by debt, equity or reserves.
Key numbers
| Number | Value | Assessment | Normal range |
|---|---|---|---|
| P/E (TTM) | 88.0 | Expensive vs peers | 37.0–49.3 (sector median 41.1) |
| Forward P/E | 63.1 | Profits expected to grow | below today's P/E (88.0) and near 41 |
| Price / book | 16.43 | High | 6–12 (high ROE allows more) |
| EPS (TTM) | ₹126.73 | Profitable | above ₹0 |
| Return on equity | 20.1% | Strong | 15%+ (below 10% is weak) |
| Debt / equity | 0.00 | Low debt | below 1.0 (under 0.5 is great) |
| Net margin | 27.6% | Healthy | 10%+ (below 5% is thin) |
| Operating margin | 34.0% | Strong | 20%+ strong, below 10% thin |
| Revenue growth | +35.4% | Growing well | 10%+ a year (below 3% is weak) |
| Profit growth | +63.6% | Growing well | 10%+ a year (falling is weak) |
| Dividend yield | 0.27% | Small payout | 1.5%+ (none is fine for growth firms) |
| Current ratio | 4.59 | Comfortable | 1.5+ (below 1 is tight) |
| 52W high | ₹11,824.00 | 6% below · near the high | price in the top 40% of its 52-week range |
| 52W low | ₹5,647.50 | Price is 97% above it | |
| 50-DMA | ₹9,663.20 | Price 15.4% above | price above it = short-term uptrend |
| 200-DMA | ₹7,559.33 | Price 47.5% above | price above it = long-term uptrend |
| 1Y return | +66.6% | Beat the Nifty 50 | Nifty 50 did −0.4% |
| Beta | 0.18 | Steadier than the market | 0.8–1.3 (1 = moves with market) |
| Promoter / insider | 52.0% | Owners have a big stake | 50%+ shows owner commitment |
| Institutions | 29.9% | Moderate interest | 30%+ is strong |
| Analyst target | ₹11,083.11 | 0.6% downside · 28 analysts | 8%+ upside |
Questions about DIVISLAB
What is the share price of Divi's Laboratories Limited (DIVISLAB) today?
DIVISLAB last traded at ₹11,150.00 (+0.63% on the day) on the NSE. Its 52-week range is ₹5,647.50 to ₹11,824.00. Prices are delayed and come from Yahoo Finance.
Is DIVISLAB a good stock for the long term?
StockLens rates DIVISLAB 8.0 out of 10 (Excellent) overall. Its long-term verdict is "Strong long-term candidate": Business quality and valuation clearly outweigh the weaknesses. Strengths: high ROE, low debt, uptrend. Concerns: expensive vs peers, cash burn.
Is DIVISLAB share overvalued?
DIVISLAB trades at a P/E of 88.0 against a Pharma & Healthcare median of 41.1, which StockLens rates as "Expensive vs peers". Its price-to-book ratio is 16.43.
Is DIVISLAB good for short-term trading?
The trade bias for the next few weeks is "Strong long": Trend and momentum are clearly pointing up. The price is 47.5% above its 200-day average and 14-day RSI is 69.
Which stocks are similar to DIVISLAB?
Similar Pharma & Healthcare stocks of comparable size include Sun Pharmaceutical, Torrent Pharmaceuticals, Laurus Labs, Apollo Hospitals, Zydus Lifesciences. You can compare up to 4 of them side by side on StockLens.
About Divi's Laboratories Limited
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
Stocks similar to DIVISLAB
- Sun Pharmaceutical share price
- Torrent Pharmaceuticals share price
- Laurus Labs share price
- Apollo Hospitals share price
- Zydus Lifesciences share price
- Dr. Reddy's Laboratories share price
Compare DIVISLAB with SUNPHARMA, TORNTPHARM, LAURUSLABS
Educational information, not investment advice. Data from Yahoo Finance and NSE Indices; prices may be delayed.